Summary
- Profile Type
- Business request
- POD Reference
- BRGB20240927014
- Term of Validity
- 27 September 2024 - 27 September 2025
- Company's Country
- United Kingdom
- Type of partnership
- Commercial agreement
- Investment agreement
- Outsourcing agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- This UK rare disease pharma company aims to address the treatment gap for rare diseases by matching unmet patient needs with by helping small businesses commercialise orphan drugs that would provide treatment. The company would collaborate with these small businesses through acquisitions that is buying the asset, licensing from the business or partnering with the business to bring the asset to market.
- Full Description
-
The UK company boasts a team with over 200 years of combined experience in the pharma sector, focusing on rare diseases where there is a lack of hospital analytical services and no approved drugs. They have identified a significant market gap. Their core markets include the EU, US, and ME, helping hospital providers enhance understanding of rare disease patient populations .
The company is actively developing a portfolio of commercial and clinical-stage therapeutic assets through acquisition, licensing, and collaborations. This strategic approach allows for rapid integration of innovative therapies, supporting expedited clinical trials and regulatory approvals. - Advantages and Innovations
-
• Leadership team with extensive experience and international connections in the pharma industry.
• Application of expertise specifically in the rare disease sector.
• Utilization of analytical tools to deliver superior insights into patient populations, facilitating drug portfolio development for effective treatment - Technical Specification or Expertise Sought
- Developers of orphan drugs in the rare disease field who have been unable to commercialize their products.
- Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- No IPR applied
Partner Sought
- Expected Role of a Partner
-
The company seeks partners who are either the owners or innovators behind orphan drugs that have been unable to commercialize, considering a range of development stages. Partners may pursue options for acquisition, licensing, and collaborations.
Additionally, the company is interested in collaborating with partners who have laboratory facilities for developing drug strains, facilitating further advancements in therapeutic asset development . - Type and Size of Partner
- University
- R&D Institution
- SME <=10
- SME 11-49
- Type of partnership
- Commercial agreement
- Investment agreement
- Outsourcing agreement
Dissemination
- Technology keywords
- 06001006 - Human vaccines
- Market keywords
- 05005022 - Other clinical medicine
- 05007002 - Pharmaceuticals/fine chemicals
- 05005008 - Internal medicine
- 05007007 - Other medical/health related (not elsewhere classified)
- 05006 - Anatomy, Pathology, Immunology, Physiology
- Sector Groups Involved
- Health
- Targeted countries
- All countries